PMID- 36862897
OWN - NLM
STAT- MEDLINE
DCOM- 20230306
LR  - 20230626
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Print)
IS  - 0025-7974 (Linking)
VI  - 102
IP  - 9
DP  - 2023 Mar 3
TI  - HLA-A and HLA-B genes are involved in the pathogenesis of IBS.
PG  - e33135
LID - 10.1097/MD.0000000000033135 [doi]
LID - e33135
AB  - Irritable bowel syndrome (IBS) is the most common functional gastrointestinal 
      disorder. The pathogenesis of IBS has not yet been fully elucidated, and the 
      relationship between human leukocyte antigen (HLA) class I molecules and IBS is 
      not clear. The present case-control study investigated the correlation between 
      HLA-A and HLA-B genes and IBS. Peripheral blood samples were collected from 102 
      IBS patients and 108 healthy volunteers at Nanning First People's Hospital. DNA 
      was extracted using a routine procedure, and HLA-A and HLA-B gene polymorphisms 
      were identified by polymerase chain reaction with sequence-specific primers to 
      determine the genotype and distribution frequency of HLA-A and HLA-B in IBS 
      patients and healthy controls. Susceptibility and protective genes for IBS were 
      identified using univariate and multivariate analyses. The frequency of HLA-A11 
      gene expression in the IBS group was significantly higher than that in the 
      healthy control group, while the frequencies of HLA-A24, 26, and 33 gene 
      expression were significantly higher in the healthy control group than in the IBS 
      group (all P < .05). The frequencies of HLA-B56 and 75 (15) gene expression in 
      the IBS group were significantly higher than those in the healthy control group, 
      while the frequencies of HLA-B46 and 48 gene expression were significantly higher 
      in the healthy control group than in the IBS group (all P < .05). Genes that may 
      be related to the prevalence of IBS were included in the multivariate logistic 
      regression, and the results suggested that the HLA-B75 (15) gene is a 
      susceptibility gene for IBS (P = .031, odds ratio [OR] = 2.625, 95% confidence 
      interval [CI]: 1.093-6.302), while the HLA-A24 (P = .003, OR = 0.308, 95% CI: 
      0.142-0.666), A26 (P = .009, OR = 0.162, 95% CI: 0.042-0.629), A33 (P = .012, OR 
      = 0.173, 95% CI: 0.044-0.679), and B48 (P = .008, OR = 0.051, 95% CI: 
      0.006-0.459) genes are protective genes for IBS.
CI  - Copyright (c) 2023 the Author(s). Published by Wolters Kluwer Health, Inc.
FAU - Liang, Huiping
AU  - Liang H
AD  - Department of Medicine, Guangxi Medical College, Nanning, China.
FAU - Li, Li
AU  - Li L
AD  - Department of Medicine, Guangxi Medical College, Nanning, China.
FAU - Huang, Lan
AU  - Huang L
AD  - Dean's Office of Guangxi Medical College, Nanning, China.
FAU - Lu, Tingting
AU  - Lu T
AD  - Department of Medical Technology, Guangxi Medical College, Nanning, China.
FAU - Luo, Qi
AU  - Luo Q
AD  - The First People's Hospital of Nanning, Nanning, China.
FAU - Mao, Yanning
AU  - Mao Y
AD  - The First People's Hospital of Nanning, Nanning, China.
FAU - Liu, Huaying
AU  - Liu H
AUID- ORCID: 0000-0003-0230-537
AD  - Department of Medicine, Guangxi Medical College, Nanning, China.
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (HLA-A24 Antigen)
RN  - 0 (HLA-A Antigens)
RN  - 0 (HLA-B Antigens)
SB  - IM
MH  - Humans
MH  - *Irritable Bowel Syndrome/genetics
MH  - HLA-A24 Antigen
MH  - HLA-A Antigens/genetics
MH  - HLA-B Antigens
MH  - Genotype
PMC - PMC9981385
COIS- The authors have no conflicts of interest to disclose.
EDAT- 2023/03/03 06:00
MHDA- 2023/03/07 06:00
PMCR- 2023/03/03
CRDT- 2023/03/02 15:13
PHST- 2023/03/02 15:13 [entrez]
PHST- 2023/03/03 06:00 [pubmed]
PHST- 2023/03/07 06:00 [medline]
PHST- 2023/03/03 00:00 [pmc-release]
AID - 00005792-202303030-00046 [pii]
AID - 10.1097/MD.0000000000033135 [doi]
PST - ppublish
SO  - Medicine (Baltimore). 2023 Mar 3;102(9):e33135. doi: 10.1097/MD.0000000000033135.